Long Term Renal Function in Asian HIV-1 Infected Adults Receiving Tenofovir Disoproxil Fumarate Without Protease Inhibitors

Overview

Journal J Infect

Specialty Infectious Diseases

Date 2019 Aug 12

PMID 31401085

Citations 1

Authors

Geoffroy Liegeon

Linda Harrison

Anouar Nechba

Guttiga Halue

Sukit Banchongkit

Ampaipith Nilmanat

Naruepon Yutthakasemsunt

Panita Pathipvanich

Suchart Thongpaen

Rittha Lertkoonalak

Thomas Althaus

Marc Lallemant

Jean-Yves Mary

Gonzague Jourdain

Affiliations

Soon will be listed here.

Abstract

Objectives: The risk of kidney dysfunction on the WHO recommended first line regimens containing tenofovir disoproxil fumarate (TDF) without protease inhibitors (PI) remains unclear in Asian patients, especially those with low body weight.

Methods: Using data collected in a multicenter clinical trial in Thailand and proportional hazard regression models, we compared the risk of a >25% estimated glomerular filtration rate (eGFR) reduction in HIV naïve patients initiating TDF or zidovudine (AZT) containing non-PI regimen.

Results: Of 640 patients included in the analysis, 461 (72%) received a TDF-containing regimen for a median 6.7 years and 179 (28%) an AZT-containing regimen for 6.5 years. The risk of a >25% eGFR reduction was not associated with treatment (HR 1.11, 95% CI 0.84-1.47, P = 0.46). In multivariate analysis, the risk of >25% eGFR reduction form baseline was associated with body weight at baseline (HR 2.12, 95% CI 1.48-3.02 for <48 kg patients and HR 1.64, 95% CI 1.20-2.25 for 48-59.9 kg patients, compared to those with >60 kg, P < 0.001) and hypertension (HR 4.03, 95% CI 2.0-8.0, P < 0.001). The effect of baseline weight on >25% eGFR reduction did not significantly vary with treatment (P = 0.27).

Conclusions: The risk of eGFR reduction was not higher on TDF- versus AZT-based non-PI regimens. Although the risk of eGFR reduction was greater for patients of lower body weight, this risk was not significantly increased by TDF.

Citing Articles

Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program.

Paengsai N, Noppakun K, Jourdain G, Cressey T, Salvadori N, Chaiwarith R Healthcare (Basel). 2022; 10(8).

PMID: 36011147 PMC: 9408286. DOI: 10.3390/healthcare10081490.

References

Viglietti D, Verine J, de Castro N, Scemla A, Daudon M, Glotz D . Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir. Antivir Ther. 2011; 16(1):119-21. DOI: 10.3851/IMP1700. View

Gupta S, Eustace J, Winston J, Boydstun I, Ahuja T, Rodriguez R . Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005; 40(11):1559-85. DOI: 10.1086/430257. View

Pruvost A, Negredo E, Theodoro F, Puig J, Levi M, Ayen R . Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009; 53(5):1937-43. PMC: 2681534. DOI: 10.1128/AAC.01064-08. View

Ryom L, Mocroft A, Kirk O, Worm S, Kamara D, Reiss P . Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013; 207(9):1359-69. PMC: 3610424. DOI: 10.1093/infdis/jit043. View

Levey A, Coresh J, Greene T, Marsh J, Stevens L, Kusek J . Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53(4):766-72. DOI: 10.1373/clinchem.2006.077180. View

Quesada P, Lopez Esteban L, Garcia J, Vazquez Sanchez R, Molina Garcia T, Alonso-Vega G . Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015; 37(5):865-72. DOI: 10.1007/s11096-015-0132-1. View

Lucas G, Ross M, Stock P, Shlipak M, Wyatt C, Gupta S . Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(9):e96-138. PMC: 4271038. DOI: 10.1093/cid/ciu617. View

Cihlar T, Ray A, Laflamme G, Vela J, Tong L, Fuller M . Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther. 2007; 12(2):267-72. View

Praditpornsilpa K, Townamchai N, Chaiwatanarat T, Tiranathanagul K, Katawatin P, Susantitaphong P . The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant. 2011; 26(9):2780-5. DOI: 10.1093/ndt/gfq815. View

10.

Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T . Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One. 2012; 7(1):e29977. PMC: 3252345. DOI: 10.1371/journal.pone.0029977. View

11.

Praditpornsilpa K, Avihingsanon A, Chaiwatanarat T, Chaiyahong P, Wongsabut J, Ubolyam S . Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients. AIDS. 2012; 26(14):1781-8. PMC: 3782632. DOI: 10.1097/QAD.0b013e328356480d. View

12.

Mizushima D, Tanuma J, Dung N, Dung N, Trung N, Lam N . Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study. J Infect Chemother. 2014; 20(12):784-8. DOI: 10.1016/j.jiac.2014.08.015. View

13.

Jourdain G, Le Coeur S, Ngo-Giang-Huong N, Traisathit P, Cressey T, Fregonese F . Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med. 2013; 10(8):e1001494. PMC: 3735458. DOI: 10.1371/journal.pmed.1001494. View

14.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

15.

Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y . Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort. AIDS Patient Care STDS. 2017; 31(3):105-112. PMC: 5359640. DOI: 10.1089/apc.2016.0286. View

16.

Rollot F, Nazal E, Chauvelot-Moachon L, Kelaidi C, Daniel N, Saba M . Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003; 37(12):e174-6. DOI: 10.1086/379829. View

17.

Pendse R, Gupta S, Yu D, Sarkar S . HIV/AIDS in the South-East Asia region: progress and challenges. J Virus Erad. 2017; 2(Suppl 4):1-6. PMC: 5353351. View

18.

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E . Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011; 6(7):e22661. PMC: 3143186. DOI: 10.1371/journal.pone.0022661. View

19.

Patel K, Patel A, Ranjan R, Patel A, Patel J . Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis AIDS. 2011; 31(1):30-4. PMC: 3140146. DOI: 10.4103/0253-7184.68998. View

20.

Cocchetto D, Tschanz C, Bjornsson T . Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit. 1983; 5(2):161-8. DOI: 10.1097/00007691-198306000-00002. View